Immediate Impact

67 standout
Sub-graph 1 of 20

Citing Papers

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
2025 Standout
Colorectal cancer
2024 Standout
7 intermediate papers

Works of Manuel Chaves-Conde being referenced

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC)
2006

Author Peers

Author Last Decade Papers Cites
Manuel Chaves-Conde 330 127 114 24 479
D. P. Ryan 233 174 91 31 497
J Faintuch 319 97 64 24 478
Sinéad Noonan 232 281 140 26 464
Dong‐Hao Wu 255 85 114 34 536
Emiddio Barletta 388 329 90 28 569
Keizo Sugimachi 185 132 231 14 536
Huilin Xu 313 168 106 34 486
Jean Pierre Lotz 362 125 114 21 552
Jingjuan Zhu 196 188 143 26 458
Mary Collier 330 154 228 24 552

All Works

Loading papers...

Rankless by CCL
2026